Rosy Luo, PhD

Medical School Department Biostatistics
Research Program Breast Cancer Research
Rosy Luo

Researcher Background

Primary Academic Title

Professor of Surgery, Division of Public Health Sciences, WashU Medicine

Education

  • 2001: MS, Renmin University, Beijing
  • 2004: MS, Duke University, Durham, NC
  • 2006: PhD, Duke University, Durham, NC

Research & Selected Publications

Research Interest

Statistical analysis of microarray gene expression data and proteomics data, ranging from power calculation to biomarker identification and patient classification.

Research Publications

Long-acting interleukin-7 improves the efficacy of oncolytic viral therapy in glioblastoma.
Authors:

Li YD, Giles DA, Huang Y, one or more additional authors omitted Luo J, one or more additional authors omitted Chheda MG

Journal & Year:

Nat Commun • 2026

Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial.
Authors:

Kong T, Mabry A, Highkin M, one or more additional authors omitted Luo J, Ma CX

Journal & Year:

Nat Commun • 2026

Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host.
Authors:

Gonzalez-Aponte MF, Damato AR, Simon T, one or more additional authors omitted Luo J, one or more additional authors omitted Herzog ED

Journal & Year:

Cancer Cell • 2025

SHP2 as a primordial epigenetic enzyme expunges histone H3 pTyr-54 to amend androgen receptor homeostasis.
Authors:

Chouhan S, Sridaran D, Weimholt C, Luo J, one or more additional authors omitted Mahajan NP

Journal & Year:

Nat Commun • 2024

SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production.
Authors:

Chen L, Shi V, Wang S, one or more additional authors omitted Luo J, one or more additional authors omitted Markovina S

Journal & Year:

J Clin Invest • 2023